{"id":"stw-5-ii","safety":{"commonSideEffects":[{"rate":null,"effect":"Gastrointestinal disturbances"},{"rate":null,"effect":"Allergic reactions"}]},"_chembl":{"chemblId":"CHEMBL229670","moleculeType":"Small molecule","molecularWeight":"354.40"},"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"STW 5-II contains a standardized extract of nine medicinal plants that work synergistically to improve gastric emptying, reduce visceral pain, and normalize intestinal secretion. The formulation addresses multiple pathophysiological mechanisms underlying functional dyspepsia and irritable bowel syndrome through its spasmolytic, prokinetic, and anti-inflammatory properties.","oneSentence":"STW 5-II is a herbal combination product that modulates gastrointestinal motility and secretion to relieve functional gastrointestinal symptoms.","_ai_confidence":"medium"},"_scrapedAt":"2026-03-28T00:09:48.961Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Functional dyspepsia"},{"name":"Irritable bowel syndrome"}]},"trialDetails":[{"nctId":"NCT07198243","phase":"PHASE4","title":"The Effects of STW 5-II on Duodenal Mucosa and Symptoms in Functional Dyspepsia","status":"NOT_YET_RECRUITING","sponsor":"Universitaire Ziekenhuizen KU Leuven","startDate":"2025-09-30","conditions":"Functional Dyspepsia","enrollment":100},{"nctId":"NCT05389709","phase":"","title":"A Pharmacy-based Observational Study to Learn More About Iberogast Advance in the Real-world Setting","status":"COMPLETED","sponsor":"Bayer","startDate":"2022-06-04","conditions":"Functional Gastrointestinal Disorders Such as Irritable Bowel Syndrome and Functional Dyspepsia, Irritable Bowel Syndrome, Functional Dyspepsia","enrollment":184}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":19,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"marketed","status":"active","brandName":"STW 5-II","genericName":"STW 5-II","companyName":"Universitaire Ziekenhuizen KU Leuven","companyId":"universitaire-ziekenhuizen-ku-leuven","modality":"Small molecule","firstApprovalDate":"","aiSummary":"STW 5-II is a treatment being studied for Functional Dyspepsia, a type of Functional Gastrointestinal Disorder. It is being compared to a placebo in a clinical trial to assess its effects on duodenal mucosa and symptoms in patients with Functional Dyspepsia.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}